<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The PRDM16 (1p36) gene is rearranged in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) with t(1;3)(p36;q21), sharing characteristics with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with MECOM (3q26.2) translocations </plain></SENT>
<SENT sid="1" pm="."><plain>We used fluorescence in situ hybridization to study 39 haematological <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> with translocations involving PRDM16 to assess the precise breakpoint on 1p36 and the identity of the partner locus </plain></SENT>
<SENT sid="2" pm="."><plain>Reverse-transcription polymerase chain reaction (PCR) was performed in selected cases in order to confirm the partner locus </plain></SENT>
<SENT sid="3" pm="."><plain>PRDM16 expression studies were performed on bone marrow samples of patients, <z:mpath ids='MPATH_458'>normal</z:mpath> controls and CD34(+) cells using TaqMan real-time quantitative PCR </plain></SENT>
<SENT sid="4" pm="."><plain>PRDM16 was rearranged with the RPN1 (3q21) locus in 30 cases and with other loci in nine cases </plain></SENT>
<SENT sid="5" pm="."><plain>The diagnosis was <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in most cases, except for two cases of lymphoid proliferation </plain></SENT>
<SENT sid="6" pm="."><plain>We identified novel translocation partners of PRDM16, including the transcription factors ETV6 and IKZF1 </plain></SENT>
<SENT sid="7" pm="."><plain>Translocations involving PRDM16 lead to its overexpression irrespective of the consequence of the rearrangement (fusion gene or promoter swap) </plain></SENT>
<SENT sid="8" pm="."><plain>Survival data suggest that patients with <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> and PRDM16 translocations have a poor prognosis despite a simple karyotype and a median age of 65 years </plain></SENT>
<SENT sid="9" pm="."><plain>There seems to be an over-representation of <z:hpo ids='HP_0003584'>late-onset</z:hpo> therapy-related <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> </plain></SENT>
</text></document>